Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement

You may also be interested in...

Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec

SEOUL - Seoul's Administrative Court ruled in favor of Novartis and suspended the Korean health ministry's plan to cut the price of the Swiss-based company's leukemia drug Glivec (imatinib) by 14 percent beginning Sept. 15

Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights

MUMBAI - For the two Swiss drug giants Novartis and Roche, there was much action at India's Supreme Court Aug. 28 as they separately continued the fight to safeguard patents on their life-saving oncology drugs steadfastly challenged by health activists and generic drug manufacturers alike in India

Korea-EU Free Trade Agreement Creates Another Threat To Local Korean Pharmas; Good For MNCs

SEOUL - The conclusion of the Free Trade Agreement talks on July 13 with the European Union could deal another blow to generic-dependent local South Korean pharma companies, already hit by a similar pact pending with the U.S

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts